ALK4290
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].
Product Specifications
CAS Number
1251528-23-0
Product Name Alternative
AKST4290
UNSPSC
12352005
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/alk4290.html
Purity
99.79
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC(NC([C@@H](CC2)N(C3CCN(CC4=CC=C(Cl)C(C)=C4)CC3)C2=O)=O)=NC(C)=C1)N(C)C
Molecular Formula
C27H34ClN5O3
Molecular Weight
512.04
References & Citations
[1]NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.|[2]Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila) . May-Jun 2020; 9 (3) :250-259.|[3]Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CCR3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
